Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DUT | P33316 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17891895 | 0.88 | DUT (0.36) | DUT | |
| SCHEMBL368374 | 0.85 | DUT (0.30) | DUT | |
| SCHEMBL2142279 | 0.84 | DUT (0.34) | DUT | |
| SCHEMBL7698447 | 0.80 | CYP4F2 (0.33) | DUT | |
| SCHEMBL2151865 | 0.80 | DUT (0.32) | DUT | |
| SCHEMBL223234 | 0.77 | NUDT1 (0.33) | — | |
| SCHEMBL738264 | 0.77 | DUT (0.34) | DUT | |
| SCHEMBL1314515 | 0.77 | DUT (0.34) | DUT | |
| SCHEMBL11580466 | 0.75 | DUT (0.42) | DUT | |
| SCHEMBL2151576 | 0.75 | DUT (0.36) | DUT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240400520-A1 | 5-METHYL-6-PHENYL-4,5-DIHYDRO-2H-PYRIDAZIN-3-ONE DERIVATIVE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2024-12-05 | — | — | US | disclosed |
| CN-108779076-B | 5-methyl-6-phenyl-4, 5-dihydro-2H-pyridazin-3-one derivatives | 大塚制药株式会社 | 2022-05-03 | — | — | CN | disclosed |
| EP-3423440-B9 | 5-METHYL-6-PHENYL-4,5-DIHYDRO-2H-PYRIDAZIN-3-ONE DERIVATIVE FOR THE TREATMENT OF BRAIN TUMORS | OTSUKA PHARMA CO LTD (JP) | 2021-07-28 | — | — | EP | disclosed |
| US-20210171472-A1 | 5-METHYL-6-PHENYL-4,5-DIHYDRO-2H-PYRIDAZIN-3-ONE DERIVATIVE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2021-06-10 | — | — | US | disclosed |
| EP-3423440-B1 | 5-METHYL-6-PHENYL-4,5-DIHYDRO-2H-PYRIDAZIN-3-ONE DERIVATIVE FOR THE TREATMENT OF BRAIN TUMORS | OTSUKA PHARMA CO LTD (JP) | 2021-01-06 | — | — | EP | disclosed |
| US-20200181092-A1 | 5-METHYL-6-PHENYL-4,5-DIHYDRO-2H-PYRIDAZIN-3-ONE DERIVATIVE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-06-11 | — | — | US | disclosed |
| US-10611731-B2 | 5-methyl-6-phenyl-4,5-dihydro-2H-pyridazin-3-one derivative | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2020-04-07 | — | — | US | disclosed |
| US-20190023662-A1 | 5-METHYL-6-PHENYL-4,5-DIHYDRO-2H-PYRIDAZIN-3-ONE DERIVATIVE | OTSUKA PHARMACEUTICAL CO., LTD. (JP) | 2019-01-24 | — | — | US | disclosed |
| EP-3423440-A1 | 5-METHYL-6-PHENYL-4,5-DIHYDRO-2H-PYRIDAZIN-3-ONE DERIVATIVE | Otsuka Pharmaceutical Co., Ltd. (JP) | 2019-01-09 | — | — | EP | disclosed |
| US-8426388-B2 | Prodrugs of HIV protease inhibitors | ABBVIE INC. (US) | 2013-04-23 | — | — | US | disclosed |
| EP-1773850-B1 | PRODRUGS OF HIV PROTEASE INHIBITORS | ABBOTT LAB (US) | 2013-01-30 | — | — | EP | disclosed |
| US-20100286032-A1 | PRODRUGS OF HIV PROTEASE INHIBITORS | ABBOTT LABORATORIES (US) | 2010-11-11 | — | — | US | disclosed |
| US-7718633-B2 | Prodrugs of HIV protease inhibitors | ABBOTT LABORATORIES (US) | 2010-05-18 | — | — | US | disclosed |
| US-20070270383-A1 | Prodrugs of HIV protease inhibitors | ABBVIE INC. | 2007-11-22 | — | — | US | disclosed |
| EP-0558959-B1 | Phosphonooxy and carbonate derivatives of taxol | BRISTOL MYERS SQUIBB CO (US) | 1997-04-16 | — | — | EP | disclosed |
| US-5272171-A | Phosphonooxy and carbonate derivatives of taxol | BRISTOL-MYERS SQUIBB COMPANY (US) | 1993-12-21 | — | — | US | disclosed |
| EP-0558959-A1 | Phosphonooxy and carbonate derivatives of taxol | Bristol-Myers Squibb Company (US) | 1993-09-08 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (7 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210171472-A1 | 5-METHYL-6-PHENYL-4,5-DIHYDRO-2H-PYRIDAZIN-3-ONE DERIVATIVE | VHL, H1-5, PRMT5 | DUT 294/4885 |
| US-20200181092-A1 | 5-METHYL-6-PHENYL-4,5-DIHYDRO-2H-PYRIDAZIN-3-ONE DERIVATIVE | VHL, H1-5, PRMT5 | DUT 294/4885 |
| US-20240400520-A1 | 5-METHYL-6-PHENYL-4,5-DIHYDRO-2H-PYRIDAZIN-3-ONE DERIVATIVE | VHL, H1-5, PRMT5 | DUT 294/4885 |
| US-20100286032-A1 | PRODRUGS OF HIV PROTEASE INHIBITORS | PREP, PEPD, SERPINB1 | DUT 221/4885 |
| US-20190023662-A1 | 5-METHYL-6-PHENYL-4,5-DIHYDRO-2H-PYRIDAZIN-3-ONE DERIVATIVE | VHL, H1-5, PRMT5 | DUT 294/4885 |
| US-20070270383-A1 | Prodrugs of HIV protease inhibitors | PREP, PEPD, SERPINB1 | DUT 221/4885 |
| US-10611731-B2 | 5-methyl-6-phenyl-4,5-dihydro-2H-pyridazin-3-one derivative | VHL, H1-5, PRMT5 | DUT 294/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.